SPDR SSgA多资产实际回报ETF RLY 深 沪
已收盘 12-19 16:00:00 美东时间
31.8199
+0.130
+0.41%
华盛通- 最 高32.1493
- 今 开31.87
- 成交量 6.70万股
- 最 低 30.99
- 昨 收 31.69
- 总市值 4.65亿
- 52周最高 32.1493
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 25.63
- 委 比 0.00%
- 总股本 1460.00万
- 历史最高 32.1493
- 量 比 1.03
- 振 幅 3.66%
- 历史最低 10.2763
- 每 手 1
- 风险率 1.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
<p>Relay Therapeutics, Inc. announced the appointment of Dr. Claire Mazumdar to its Board of Directors. Dr. Mazumdar brings extensive experience in clinical-stage oncology and drug development, particularly in precision medicine. She previously founded Bicara Therapeutics and led business development at Rheos Medicines, collaborating with Roche Pharmaceuticals. With her expertise, she will support Relay Therapeutics in advancing its drug discovery efforts.</p>
06-11 20:05
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Relay Therapeutics reported promising interim data for RLY-2608, showing a median progression-free survival (PFS) of 10.3 months overall and 11.0 months for second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The data support the planned Phase 3 ReDiscover-2 study to begin mid-2025 and highlight RLY-2608's improved tolerability and efficacy compared to current treatments. Next-generation triplet combinations with atirmociclib and ribociclib are also being evaluated.
06-02 11:00
